Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
copper cu 64 NOTA-PSMAi-PEG-Cy5.5-C' dots
- Development stage
- Phase 1
- Lead developer
- Elucida Oncology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Copper Cu 64 NOTA-PSMAi-PEG-Cy5.5-C' dots are ultrasmall, renally clearable silica nanoparticles functionalized with a prostate-specific membrane antigen inhibitor (PSMAi), a polyethylene glycol (PEG) linker, and the fluorescent dye Cy5.5, radiolabeled with copper isotope Cu‑64 for PET imaging[1][2][7]. The PSMAi moiety enables selective targeting and binding to PSMA expressed on tumor cells, particularly in prostate cancer[1][2]. Upon administration, these nanoparticles accumulate in PSMA-expressing tumors and can be visualized using positron emission tomography (PET) due to the radioactive Cu‑64 label; the Cy5.5 dye allows for intraoperative fluorescence imaging[1][2][7]. Developed by Elucida Oncology, this agent is primarily intended as a diagnostic radiopharmaceutical for detecting prostate cancer lesions and guiding surgical resection[2][3].
- Other names
- copper cu 64 NOTA-PSMAi-PEG-Cy5.5-C' dots
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on copper cu 64 NOTA-PSMAi-PEG-Cy5.5-C' dots.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on copper cu 64 NOTA-PSMAi-PEG-Cy5.5-C' dots.